KDR and neoplasm: Vandetanib is an oral inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), epidermal growth factor receptor (EGFR), and Ret tyrosine kinases involved in tumor growth, progression, and angiogenesis34.